MYELOFIBROSIS - PIPELINE REVIEW, H2 2013

Myelofibrosis - Pipeline Review, H2 2013

'Myelofibrosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Myelofibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelofibrosis. Myelofibrosis - Pipeline Review

Read » Myelofibrosis - Pipeline Review, H2 2013

Published 1 year 31 weeks ago – Made popular 1 year 31 weeks ago
Category: Health | Tags:

Login or register to post comments

Stories similar to Myelofibrosis - Pipeline Review, H2 2013:

Additional information on Myelofibrosis - Pipeline Review, H2 2013 :
- Sep 11, 2014 ... ... of the "Essential Thrombocythemia - Pipeline Review, H2 2014" report to ... Research and Markets: Myelofibrosis - Pipeline Review, H1 2013.
- May 30, 2015 ... PipelineReview.com ... "Myelofibrosis is a difficult-to-treat, rare chronic blood cancer in need of .... The FDA's Fast Track process is designed to facilitate the development and expedite the review of ... entered into a worldwide license agreement in November 2013 to develop and commercialize pacritinib.
- Feb 13, 2014 ... Idelalisib's iNHL indication is scheduled to be reviewed by the FDA on ... By comparison, sales of Letairis rose 27% year over year to $520 million in 2013. ... momelotinib as a treatment for the blood disorder myelofibrosis.
- Dec 12, 2012 ... The transaction is expected to close in the first quarter of 2013. ... in 166 patients with myelofibrosis, a life-threatening myeloproliferative disease. ... Hart Scott Rodino Antitrust Improvements Act, and the review period under the ... of Gilead to advance YM's product pipeline, including CYT387, the possibility ...
- 1 day ago ... (Before It's News). Global Markets Direct's, 'Post-Polycythemia Vera Myelofibrosis (PPV-MF) Pipeline Review, H1 2015′, provides an overview ...
- Feb 19, 2013 ... Instructions for Authors · Join Peer Review ... February 2013 Vol 6, No 1, Special Issue - Health Economics .... improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis.
- Jul 17, 2013 ... 2013 Nov; 98(11): 1689–1696. ... The primary myelofibrosis genome had a low somatic mutation rate, consistent with that ... generally in a small minority of cases (reviewed by Tefferi et al. and Abdel-Wahab et al.). ... using CASAVA version 1.8 and the HugeSeq pipeline version 1.0, which uses BWA for ...
- Nov 7, 2013 ... 7, 2013-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that ... data from studies of idelalisib, which is currently under review by the U.S. Food ... the potential of idelalisib for the treatment of myelofibrosis (#4065).

Related links about Myelofibrosis - Pipeline Review, H2 2013 :
1. Post-Polycythemia Vera Myelofibrosis Pipeline Review, H1 2015 ...
2. Phase 3 Pacritinib Study Shows Significant Clinically Meaningful ...
3. Gilead | Investors | News Release
4. Hematologic Drug Pipeline Is Bustling
5. Comprehensive whole-genome sequencing of an early-stage ...

Myelofibrosis-Pipeline Insights, 2014 31 weeks 2 days ago: SUMMARY
Arrhythmias - Pipeline Review Market 1 year 32 weeks ago: 'Arrhythmias - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Arrhythmias, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arrhythmias.
Sepsis - Pipeline Review Market 1 year 32 weeks ago: Sepsis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sepsis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sepsis.
Thrombocythaemia Myelofibrosis-Pipeline Insights, 2014 29 weeks 5 days ago: SUMMARY
Epidermolysis Bullosa - Pipeline Review, H2 2013 1 year 29 weeks ago: Epidermolysis Bullosa - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Epidermolysis Bullosa, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa.